Table 1 Clinical characteristics of patients
Features (mean + SD) | Training set | Test set | p-value |
|---|---|---|---|
157 (80%) | 40 (20%) | ||
Age (years) | 66.24 ± 7.85 | 64.65 ± 7.22 | 0.2506 |
PSA | 96.88 ± 230.79 | 100.68 ± 220.24 | 0.9257 |
Neutrophil percentage (%) | 61.70 ± 10.42 | 58.53 ± 10.81 | 0.0914 |
Neutrophils (×109/L) | 3.94 ± 1.81 | 3.70 ± 1.41 | 0.3583 |
Lymphocyte percentage (%) | 26.31 ± 8.86 | 28.82 ± 9.01 | 0.1130 |
Lymphocytes (×109/L) | 1.55 ± 0.53 | 1.73 ± 0.65 | 0.0770 |
Hemoglobing (/L) | 132.43 ± 15.32 | 136.15 ± 14.17 | 0.1673 |
ALT (U/L) | 19.77 ± 13.50 | 21.77 ± 15.55 | 0.4202 |
Alkaline phosphatase (U/L) | 143.60 ± 382.69 | 117.65 ± 234.60 | 0.5937 |
Lactate dehydrogenase | 180.68 ± 93.13 | 164.40 ± 26.21 | 0.0587 |
Serum creatinine (mmol/l) | 87.45 ± 45.94 | 100.85 ± 85.84 | 0.1834 |
T cells (CD3+CD19−) (%) | 67.70 ± 9.47 | 69.24 ± 8.08 | 0.3470 |
T cells (CD3+CD19−) (/μl) | 1040.21 ± 314.91 | 1173.60 ± 462.04 | 0.0334* |
B cells (CD3−CD19+) (%) | 12.14 ± 5.54 | 13.07 ± 6.36 | 0.3641 |
B cells (CD3−CD19+) (/μl) | 190.44 ± 120.22 | 240.05 ± 193.13 | 0.0451* |
Th cells (CD3+CD4+) (%) | 43.41 ± 8.56 | 46.49 ± 7.72 | 0.0406* |
Th cells (CD3+CD4+) (/μl) | 666.55 ± 222.74 | 801.12 ± 364.37 | 0.0038* |
Ts cells (CD3+CD8+) (%) | 20.70 ± 6.59 | 19.48 ± 6.53 | 0.3002 |
Ts cells (CD3+CD8+) (/μl) | 318.72 ± 134.72 | 315.95 ± 124.61 | 0.9068 |
NK cells (CD3−/CD16+CD56+) (%) | 19.37 ± 9.65 | 16.86 ± 7.90 | 0.1318 |
NK cells (CD3−/CD16+CD56+) (/μl) | 307.17 ± 204.40 | 267.38 ± 132.43 | 0.1409 |
T cells + B cells + NK cells (%) | 99.22 ± 0.64 | 99.18 ± 0.98 | 0.7586 |
T cells + B cells + NK cells (/μl) | 1537.82 ± 463.60 | 1681.03 ± 629.11 | 0.1104 |
Th/Ts | 2.36 ± 1.02 | 2.71 ± 1.14 | 0.0612 |
Th cells + CD28+(CD3+CD4+CD28+) (/Th) | 94.53 ± 7.10 | 93.30 ± 9.02 | 0.3579 |
Ts cells + CD28+(CD3+CD8+CD28+) (/Ts) | 58.58 ± 17.65 | 59.85 ± 16.75 | 0.6843 |
Activated T cells (CD3+HLA−DR+) (/μl) | 17.90 ± 6.33 | 17.31 ± 7.30 | 0.6113 |
Activated Ts cells (CD3+CD8+HLA−DR+)/Ts (%) | 44.46 ± 13.06 | 41.33 ± 10.24 | 0.1109 |
Naïve Th cells (CD3+CD4+CD45RA+)/Th (%) | 32.45 ± 13.49 | 35.65 ± 14.50 | 0.1910 |
Memory Th cells (CD3+CD4+CD45RO+)/Th (%) | 67.61 ± 13.57 | 64.35 ± 14.50 | 0.1843 |
Regulatory T cells (CD3+CD4+CD25+CD127low+) (/μl) | 3.82 ± 1.22 | 4.00 ± 1.34 | 0.4085 |
Naïve regulatory T cells (CD45RA+CD3+CD4+CD25+CD127low+) (/μl) | 0.76 ± 0.47 | 0.79 ± 0.50 | 0.6688 |
Induced regulatory T cells (CD45RO+CD3+CD4+CD25+CD127low+) (/μl) | 3.06 ± 0.93 | 3.21 ± 1.10 | 0.3944 |
IFN-γ+CD4+T cells /Th (%) | 21.47 ± 8.21 | 19.48 ± 6.75 | 0.1610 |
IFN-γ+CD8+T cells /Ts (%) | 62.31 ± 15.37 | 59.91 ± 13.51 | 0.3690 |
IFN-γ+NK cells/NK (%) | 74.80 ± 14.78 | 73.58 ± 13.25 | 0.6383 |
Interleukin-1β (pg/mL) | 7.38 ± 6.18 | 6.63 ± 4.87 | 0.4237 |
Interleukin-2R (U/mL) | 498.19 ± 320.20 | 533.62 ± 509.28 | 0.5878 |
Interleukin-6 (pg/mL) | 6.87 ± 12.45 | 6.78 ± 9.36 | 0.9612 |
Interleukin-8 (pg/mL) | 27.15 ± 36.89 | 36.77 ± 55.40 | 0.1927 |
Tumor necrosis factor-α (pg/mL) | 19.58 ± 31.55 | 23.62 ± 28.55 | 0.4645 |